您的当前位置:首页 > 行业数据 > 卡度尼利单抗与纳武利尤单抗联合伊匹木单抗相比安全性更优
图片属性
图片格式:PNG 图片大小:913KB 图片尺寸:1771*1076
同报告图片
 / 4
卡度尼利单抗与纳武利尤单抗联合伊匹木单抗相比安全性更优_第1页
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
卡度尼利单抗与纳武利尤单抗联合伊匹木单抗相比安全性更优_第2页
卡度尼利单抗与纳武利尤单抗联合伊匹木单抗相比安全性更优_第3页
卡度尼利单抗与纳武利尤单抗联合伊匹木单抗相比安全性更优_第4页
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
卡度尼利单抗与纳武利尤单抗联合伊匹木单抗相比安全性更优_第5页
fCDliIbmnJ8gfCDmlbDph48gfAp8IC0tLSB8IC0tLSB8CnwgSUlJ5pyfIHwgOTIgfAp8IEkvSUnmnJ8gfCA4NiB8CnwgSUnmnJ8gfCAyOTYgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM5Y2O56aP6K+B5Yi456CU56m25omA77yI5oiq6IezMjAyNOW5tDbmnIgyNeaXpe+8iQ==
所属报告: 康方生物-港股公司研究报告-肺癌大适应症先发优势占位IO 2.0的未来已来-240708(31页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠